Main Session
Sep 29
SS 42 - Advanced Lung Cancer and Drug Combinations

277 - Alteration Subtype is Prognostic of Intracranial Outcome and Predicts the Benefit of Upfront SRS in EGFR-Mutant NSCLC Brain Metastasis

01:10pm - 01:20pm ET

Presenter(s)

Emily Wo, PharmD - Memorial Sloan Kettering Cancer Center, Middletown Township, NJ